SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Social media platforms are seeing a surge in speculative chatter as investors debate the legitimacy of tokenized pre-IPO assets, with many users warning of potential scams while others track news regarding a long-rumored SpaceX public offering. Community members are actively analyzing the aerospace sector, focusing on the potential impact of a high-profile IPO and debating whether current market excitement reflects genuine valuation or a bubble driven by retail FOMO.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is attracting significant attention as investors speculate on its role in the AI-agent infrastructure space, with the community actively discussing potential institutional interest and long-term utility. Despite recent price volatility, supporters are highlighting bullish ecosystem developments and active development as reasons to maintain a long-term position.

Swell

The community is actively debating the potential of Swell, with supporters highlighting its liquid staking utility, institutional backing, and low market cap as key drivers for long-term growth. Conversely, critics frequently dismiss the asset as a speculative project, pointing to recurring price volatility and concerns over supply issuance as reasons for caution.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is gaining momentum as investors weigh its potential as a vertically integrated domestic rare earth magnet manufacturer against concerns regarding its micro-float and high insider ownership. Community discussion is split between excitement over the stock's positioning as a strategic alternative to foreign supply chains and caution regarding its characteristic high volatility and potential for sharp price swings.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

League of Degens 

The community is actively discussing $DEGEN, pointing to a mix of optimism surrounding potential exchange listings and a new beta app while others express frustration over token performance. Investors remain hyper-focused on upcoming project catalysts and social media branding as they debate whether the token is currently at a critical accumulation phase.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following an exclusive U.S. supply agreement for the Tokyo strain of BCG to address the ongoing domestic shortage, a move the community views as a strategic breakthrough that strengthens the company's competitive position against major pharmaceutical players. Investors are actively discussing the potential for accelerated regulatory pathways, the synergy between this supply and Anktiva, and the anticipation of further catalysts being revealed at the upcoming American Urological Association conference.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending as investors monitor Q4 earnings results and weigh the ongoing growth of immunology blockbusters Skyrizi and Rinvoq against the managed decline of Humira revenues. Meanwhile, community discussions are heavily focused on the company's potential M&A appetite in the obesity and oncology sectors, with retail sentiment remaining vigilant regarding potential competitive threats and pipeline expansion strategies.

WW International, Inc. engages in the provision of weight management services. It operates through the following geographical segments: United States, Germany, and Other. The company was founded by Jean Nidetch in 1963 and is headquartered in New York, NY.

WW International Inc - Ordinary Shares - New

WW International, Inc. Common Stock

WW International is gaining traction as investors speculate on a turnaround driven by strategic partnerships with GLP-1 medication providers and debt-reduction efforts. The community remains divided, with some betting on a successful pivot toward clinical weight-loss solutions while others remain skeptical due to the company's historical financial struggles and competitive pressure.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is experiencing a surge in investor interest driven by strong prescription growth, successful patent protection, and a clear path toward operating profitability in the coming quarters. The community is actively discussing the stock's potential for acquisition by larger pharmaceutical firms, while closely monitoring the ongoing battle against high short interest and institutional accumulation patterns.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

Render Token is currently capturing significant attention as investors double down on decentralized AI infrastructure and GPU-based compute plays. The community is heavily focused on the protocol's utility in the expanding AI landscape, with many traders actively accumulating positions while discussing its long-term potential compared to other artificial intelligence and DePIN projects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Due to continued war and strikes in the middle-east region, Brent crude is expected to cross $100 per barrel resulting in a bull run in oil stocks.&nbsp;</li><li>Pennzoil Quaker State Company DBA SOPUS Products, a wholly owned subsidiary of Shell USA, will sell Jiffy Lube International to an affiliate of Monomoy Capital Partners for $1.3 billion.&nbsp;</li><li>Shell will retain its Pennzoil Quaker State, Rotella and other Shell lubricants brands.</li></ul>U.S. listed shares of Shell jumped more than 2% on Monday helped by rising oil prices as well as the oil producer divesting Jiffy Lube International and Premium Velocity Auto for $1.3 billion.&nbsp;Pennzoil Quaker State Company DBA SOPUS Products, a wholly owned subsidiary of Shell USA, Inc., that comprises Shell's United States lubricants business, has entered an agreement to sell Jiffy Lube International and its subsidiary Premium Velocity Auto business to an affiliate of Monomoy Capital Partners for $1.3 billion.&nbsp;Shell is the leading deep-water operator and largest producer of oil and gas in the U.S. Gulf of America and the largest buyer of U.S. LNG.&nbsp;<h2 class="st-heading-2">Details</h2>The sale includes the Jiffy Lube brand and a network of franchised stores which are owned and operated by independent franchisees, in addition to franchised stores that are owned and operated by PVA.&nbsp;Shell will retain its Pennzoil Quaker State, Rotella and other Shell lubricants brands, along with marketing, manufacturing and distribution of lubricants in the U.S. and Canada that serve consumer, commercial and industrial sectors."By capitalizing on a strong market opportunity, this divestment allows us to monetize an asset that is not central to Shell's lubricant's portfolio in the US and reinvest in opportunities that generate higher returns," said Machteld de Haan, President, Downstream, Renewables and Energy Solutions, Shell plc.The transaction is expected to close in the second half of 2026, subject to regulatory approval and other closing conditions.<h2 class="st-heading-2">Oil Stocks In Focus&nbsp;</h2>Oil stocks have been in focus ever since war broke out between U.S.-Israel and Iran as it has led to blockade of a critical sea route of Strait of Hormuz through which almost 20% of global crude and LNG passes.&nbsp;Due to continued war and strikes in the middle-east region, Brent crude is expected to cross $100 per barrel resulting in a bull run in oil stocks.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around SHEL trended in ‘neutral’ territory amid ‘high’ message volume.&nbsp;Shares in the company have risen 17% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Shell logo displayed at a Shell gas station in Edmonton, Alberta, Canada, on March 22, 2025. 

Shell Stock Hits 52-Week High – Here’s Why

Rise in oil prices amid the ongoing conflict in the middle-east has spiked Brent crude and other energy product prices. 

Equity

Rise in oil prices amid the ongoing conflict in the middle-east has spiked Brent crude and other energy product prices. 


Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company reporting impressive quarterly results.&nbsp;Novartis posted core fourth-quarter (Q4) earnings per share (EPS) of $1.98, up from $1.53 last year, beating the consensus estimate of $1.80.&nbsp;Meanwhile, Q4 revenue reached $13.2 billion, surpassing the previous year’s $11.4 billion and analysts’ expectations of $12.84 billion.The company attributed its strong sales growth to its blockbuster heart-failure drug Entresto and arthritis medication Cosentyx.&nbsp;CEO Vas Narasimhan expressed optimism, stating, “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc [constant currency basis] and core operating income 22% cc.”&nbsp;He added that the company achieved key innovation milestones, including new drug approvals and promising data that would drive growth in the mid- to long-term.Despite the upbeat results, retail sentiment on Stocktwits was mixed. Although message volume surged into ‘extremely bullish’ territory, sentiment remained ‘bearish,’ indicating some hesitation among retail traders.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NVS_sentiment_and_message_volume_Jan_31_d92ad15174.png" alt="NVS sentiment and message volume Jan 31.png" width="1318" height="324"><figcaption>NVS sentiment and message volume Jan 31 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Novartis is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.&nbsp;Additionally, two other top-selling drugs, Tasigna for leukemia and Promacta for a blood disorder, will face generics in the U.S.However, Narasimhan reassured investors, emphasizing the company’s “tremendous replacement power” and its ability to bring new treatments to market when patents on existing drugs expire.&nbsp;He also highlighted the company’s strong pipeline, with more than 30 assets that could drive differentiated growth over the long term, including updates on its cardiovascular drug candidate pelacarsen and a key late-stage trial this year.Looking ahead, Novartis forecasted FY25 net sales growth in the mid- to high-single-digit range, with core operating income expected to grow in the high single to low double-digit range.&nbsp;The company also proposed a 6.1% increase in its dividend to 3.50 Swiss francs per share for 2024.Although <a href="https://stocktwits.com/symbol/NVS">Novartis' stock</a> has lost 0.1% over the past 12 months, it is up more than 7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 

U.S. shares of Sony Group Corp. (<a class="mention" data-mention="$SONY" data-symbol-id="SONY" href="https://stocktwits.com/symbol/SONY" target="_blank">$SONY</a>) surged over 7% pre-market Friday after the company reported a 69% jump in fiscal&nbsp;second-quarter (Q2) profit, driven by strength in its gaming and imaging divisions.&nbsp;Sony posted a profit of 338.5 billion yen (about $2.21 billion) on revenue of 2.91 trillion yen, up 3% year-over-year.&nbsp;The&nbsp;earnings per share (EPS) of 55.86 yen beat the consensus estimate of 39.84 yen, according to FactSet.The company saw robust performance in its Game &amp; Network Services and Imaging &amp; Sensing Solutions segments.&nbsp;Operating profit for the imaging business nearly doubled to 92.41 billion yen due to strong demand for image sensors, though Sony lowered its full-year sales and profit outlook for this segment.&nbsp;Despite selling only 3.8 million PlayStation 5 units this quarter — down from 4.9 million a year ago — Sony raised its annual profit forecast for the game division to 355.0 billion yen from 320.0 billion yen.Sony also launched its upgraded PlayStation 5 Pro this week, ahead of the holiday season, offering enhanced performance over the original 2020 model.&nbsp;The company revised its revenue forecast for the fiscal year ending March 2025, now expecting a 2.4% decline to 12.71 trillion yen, slightly better than the previously forecasted 3.2% drop.&nbsp;However, it maintained its outlook for a modest 1% increase in net profit to 980.0 billion yen.On Stocktwits, Sony was one of the top 30 trending tickers as of 7:30 am ET, reflecting heightened retail interest.&nbsp;<stembedurl>https://stocktwits.com/DT777/message/591690734</stembedurl>Still, Sony’s U.S.-listed shares are down over 2% year-to-date. Meanwhile, Tokyo-listed shares of the firm ended 1.2% higher on Friday.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/usm-tds-stocks-get-upgraded-by-raymond-james/cJ45RFrRaJ">Are USM, TDS Trump Trades Now? Raymond James Upgrades Mid-Cap Telecom Stocks On Reduced Regulatory Risk</a>

Sony also launched its upgraded PlayStation 5 Pro this week, ahead of the holiday season.

Sony Stock Jumps Pre-Market As Profit Booms Nearly 70%: Retail Buzz Builds

Despite selling only 3.8 million PlayStation 5 units this quarter — down from 4.9 million a year ago — Sony raised its annual profit forecast.

AVIV
American Century ETF Trust - Avantis International Large Cap Value ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest AVIV News

AVIVAmerican Century ETF Trust - Avantis International Large Cap Value ETF